<DOC>
	<DOCNO>NCT02174627</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy roxadustat treatment anemia patient chronic kidney disease dialysis .</brief_summary>
	<brief_title>Safety Efficacy Study Roxadustat Treat Anemia Patients With Chronic Kidney Disease ( CKD ) , Not Dialysis</brief_title>
	<detailed_description>This Phase 3 , multicenter , randomize , double-blind , placebo-controlled study anemic patient Stage 3 , 4 5 chronic kidney disease ( CKD ) dialysis .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>A glomerular filtration rate ( eGFR ) &lt; 60 mL/min/1.73 m2 , correspond stage 3 , 4 5 chronic kidney disease ( CKD ) accord Kidney Disease Outcomes Quality Initiative , receive dialysis . Mean 2 recent central laboratory hemoglobin ( Hb ) value screen period , obtain least 7 day apart , must &lt; 10.0 g/dL . Ferritin ≥50 ng/mL randomization . Transferrin saturation ≥15 % randomization . Serum folate level ≥ low limit normal ( LLN ) randomization . Serum vitamin B12 level ≥LLN randomization . Alanine aminotransferase aspartate aminotransferase ≤3 x upper limit normal ( ULN ) total bilirubin ≤1.5 x ULN randomization . Body weight 45 160 kg . Any erythropoietin analogue treatment within 6 week randomization . New York Heart Association Class III IV congestive heart failure enrollment Myocardial infarction , acute coronary syndrome , stroke , seizure thrombotic/thromboembolic event ( e.g. , deep vein thrombosis pulmonary embolism ) within 12 week prior randomization . History chronic liver disease ( e.g. , chronic infectious hepatitis , chronic autoimmune liver disease , cirrhosis fibrosis liver ) . Known hereditary hematologic disease thalassemia , sickle cell anemia , history pure red cell aplasia know cause anemia CKD . Known untreated retinal vein occlusion know untreated proliferative diabetic retinopathy ( risk retinal vein thrombosis ) . Diagnosis suspicion ( e.g . complex kidney cyst Bosniak Category II F , III IV ) renal cell carcinoma renal ultrasound ( imaging procedure e.g . computerize tomography scan magnetic resonance imaging conduct screen within 12 week prior randomization . Systolic blood pressure ( BP ) ≥160 mmHg diastolic BP ≥95 mmHg , within 2 week prior randomization . Patients may rescreened BP control . History prostate cancer , breast cancer malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp . Positive following : human immunodeficiency virus , hepatitis B surface antigen antihepatitis C virus antibody . Chronic inflammatory disease rheumatoid arthritis , systemic lupus erythematosus , ankylose spondylitis , psoriatic arthritis inflammatory bowel disease determine principal cause anemia . Known hemosiderosis , hemochromatosis hypercoagulable condition . Any prior organ transplant schedule organ transplantation date . Any red blood cell transfusion screen period . Any current condition lead active significant blood loss . Any treatment roxadustat hypoxiainducible factor prolyl hydroxylase inhibitor . Has receive another new chemical entity ( define compound approve marketing ) participate clinical study include drug treatment within least 1 month first administration investigation product study . ( Note : patient consent screened , randomize study previous study exclude ) . History alcohol drug abuse within 2 year prior randomization . Females childbearing potential , unless use contraception detail protocol sexual abstinence . Pregnant breastfeeding female . Known allergy investigational product ingredient . Any medical condition , include active , clinically significant infection , opinion investigator Sponsor may pose safety risk patient study , may confound safety efficacy assessment may interfere study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal ,</keyword>
	<keyword>CKD ,</keyword>
	<keyword>Roxadustat ,</keyword>
	<keyword>anemia ,</keyword>
	<keyword>non-dialysis</keyword>
</DOC>